Redhill Biopharma

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Public

Established: 2009-01-01

Employees: 113

Market Cap: $9.6M

Website: http://www.redhillbio.com

Introduction: RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the...

Clinical Trials

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

First Posted Date: 2017-01-04

Last Posted Date: 2021-02-24

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 54

Registration Number: NCT03009396

Locations: 🇵🇱
ARS MEDICA s.c., Powstancow Slaskich 56A/2, Wroclaw, Poland
🇵🇱
Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny, Zolnierska 18, Olsztyn, Poland
🇷🇸
Clinical Department of Gastroenterology and Hepatology Clinic for Internal Diseases Clinical Hospital Center Zvezdara Dimitrija Tucovica 161, Belgrade, Serbia

and more 21 locations

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Opaganib

First Posted Date: 2016-05-02

Last Posted Date: 2021-06-18

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 13

Registration Number: NCT02757326

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome With Diarrhea

Interventions: Drug: BEKINDA
Drug: Placebo

First Posted Date: 2016-04-29

Last Posted Date: 2018-08-28

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 127

Registration Number: NCT02757105

Locations: 🇺🇸
Clinsearch, Chattanooga, Tennessee, United States
🇺🇸
Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States
🇺🇸
New Phase Research & Development, Knoxville, Tennessee, United States

and more 13 locations

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

Phase 3

Completed

Conditions: Gastroenteritis
Gastritis

Interventions: Drug: RHB-102
Drug: Placebo Oral Tablet

First Posted Date: 2014-09-22

Last Posted Date: 2019-02-20

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 330

Registration Number: NCT02246439

Locations: 🇺🇸
Kern Medical Center, Bakersfield, California, United States
🇺🇸
CityDoc Urgent Care, Dallas, Texas, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 23 locations

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Phase 1

Withdrawn

Conditions: Kaposi Sarcoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: ABC294640

First Posted Date: 2014-09-03

Last Posted Date: 2017-12-07

Lead Sponsor: RedHill Biopharma Limited

Registration Number: NCT02229981

Locations: 🇺🇸
Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Phase 3

Completed

Conditions: Dyspepsia
Helicobacter Pylori Infection

Interventions: Drug: RHB-105
Drug: Placebo

First Posted Date: 2013-11-08

Last Posted Date: 2019-09-24

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 119

Registration Number: NCT01980095

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Detroit Clinical Research Center, Farmington Hills, Michigan, United States
🇺🇸
Investigative Clinical Research, Annapolis, Maryland, United States

and more 9 locations

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: RHB-104
Drug: Placebo

First Posted Date: 2013-09-26

Last Posted Date: 2020-12-08

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 331

Registration Number: NCT01951326

Locations: 🇨🇦
University of Saskatchewan Royal University Hospital, 103 Hospital Drive IBD Clinical Trials Unit Rm 2658, Saskatoon, Saskatchewan, Canada
🇵🇱
Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny Żołnierska 18, Olsztyn, Poland
🇸🇰
PIGEAS s.r.Prieložtek 1, o.,, Martin, Slovakia

and more 100 locations

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: RHB-104

First Posted Date: 2012-10-30

Last Posted Date: 2016-07-28

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 18

Registration Number: NCT01717664

Locations: 🇮🇱
RedHill MS Clinical Trials Site 001, Zefat (Safed), Israel
🇮🇱
RedHill MS Clinical Trial Site 002, Tel Aviv, Israel

ABC294640 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sphingosine kinase-2 inhibitor ABC294640

First Posted Date: 2011-12-08

Last Posted Date: 2020-01-07

Lead Sponsor: RedHill Biopharma Limited

Target Recruit Count: 22

Registration Number: NCT01488513

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy